+

WO2005099749A3 - Methods for controlling angiogenesis and cell proliferation - Google Patents

Methods for controlling angiogenesis and cell proliferation Download PDF

Info

Publication number
WO2005099749A3
WO2005099749A3 PCT/US2005/011549 US2005011549W WO2005099749A3 WO 2005099749 A3 WO2005099749 A3 WO 2005099749A3 US 2005011549 W US2005011549 W US 2005011549W WO 2005099749 A3 WO2005099749 A3 WO 2005099749A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cell proliferation
administering
angiogenesis
thrombin inhibitor
Prior art date
Application number
PCT/US2005/011549
Other languages
French (fr)
Other versions
WO2005099749A2 (en
Inventor
Cheng-Der Tony Yu
Original Assignee
Canyon Pharmaceuticals Inc
Cheng-Der Tony Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canyon Pharmaceuticals Inc, Cheng-Der Tony Yu filed Critical Canyon Pharmaceuticals Inc
Priority to AU2005232625A priority Critical patent/AU2005232625B2/en
Priority to NZ551146A priority patent/NZ551146A/en
Priority to CA2562756A priority patent/CA2562756C/en
Priority to EP05763698A priority patent/EP1753291A4/en
Priority to BRPI0509876-9A priority patent/BRPI0509876A/en
Priority to JP2007508384A priority patent/JP2007532646A/en
Publication of WO2005099749A2 publication Critical patent/WO2005099749A2/en
Publication of WO2005099749A3 publication Critical patent/WO2005099749A3/en
Priority to IL178578A priority patent/IL178578A/en
Priority to ZA2006/09219A priority patent/ZA200609219B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates generally to methods of inhibiting angiogenesis in a patient by administering an effective angiogenesis-inhibiting amount of a thrombin inhibitor, and to the treatment of disease states that result from uncontrolled cell proliferation by administering a thrombin inhibitor alone or co-administering a thrombin inhibitor with an anticancer or cytotoxic agent. Specifically, the thrombin inhibitors used in the methods of the present invention are hirudins.
PCT/US2005/011549 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation WO2005099749A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2005232625A AU2005232625B2 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation
NZ551146A NZ551146A (en) 2004-04-12 2005-04-05 Desulphatohirudin for treating prevascularised metastasised tumors
CA2562756A CA2562756C (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation using a desulphatohirudin
EP05763698A EP1753291A4 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation
BRPI0509876-9A BRPI0509876A (en) 2004-04-12 2005-04-05 methods to control angiogenesis and cell proliferation
JP2007508384A JP2007532646A (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation
IL178578A IL178578A (en) 2004-04-12 2006-10-15 Desulphatohirudin or desulphatohirudin variant for effecting regression of tumor
ZA2006/09219A ZA200609219B (en) 2004-04-12 2006-11-06 Methods for controlling angiogenesis and cell proliferation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56174104P 2004-04-12 2004-04-12
US60/561,741 2004-04-12

Publications (2)

Publication Number Publication Date
WO2005099749A2 WO2005099749A2 (en) 2005-10-27
WO2005099749A3 true WO2005099749A3 (en) 2006-08-03

Family

ID=35150501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011549 WO2005099749A2 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation

Country Status (13)

Country Link
US (3) US7795205B2 (en)
EP (1) EP1753291A4 (en)
JP (1) JP2007532646A (en)
AU (1) AU2005232625B2 (en)
BR (1) BRPI0509876A (en)
CA (1) CA2562756C (en)
IL (1) IL178578A (en)
MY (1) MY146091A (en)
NZ (1) NZ551146A (en)
SG (1) SG160323A1 (en)
TW (1) TWI362941B (en)
WO (1) WO2005099749A2 (en)
ZA (1) ZA200609219B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
USRE46830E1 (en) 2004-10-19 2018-05-08 Polypeptide Laboratories Holding (Ppl) Ab Method for solid phase peptide synthesis
US20100239650A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Isothiazolin biodelivery systems
US20100239651A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Nitrilopropionamide delivery systems
US20100239630A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Phosphonium salts delivery systems
US20100239626A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Propanediol delivery systems
US20100239627A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Quarternary ammonium salts delivery systems
US7803762B1 (en) * 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
CN104906037A (en) * 2015-06-23 2015-09-16 广西复鑫益生物科技有限公司平南分公司 Recombinant hirudin eye drop and preparation method thereof
CN110404060A (en) * 2018-04-28 2019-11-05 复旦大学 Use of thrombin inhibitors in the preparation of anti-tumor invasion and metastasis drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503829A2 (en) * 1991-03-08 1992-09-16 Ciba-Geigy Ag Hirudin for the inhibition of cancer metastasis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
DE3586333T2 (en) 1984-03-27 1992-12-10 Transgene Sa EXPRESSION VECTORS FOR HIRUDIN, TRANSFORMED CELLS AND METHOD FOR THE PRODUCTION OF HIRUDIN.
DE3438296A1 (en) 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt NEW POLYPEPTIDES WITH A BLOOD-CLOTHING EFFECT, METHOD FOR THE PRODUCTION OR THEIR RECOVERY, THEIR USE AND THE CONTAINERS THEREOF
EP0168342B1 (en) 1984-06-14 1991-07-03 Ciba-Geigy Ag Process for the preparation of thrombin inhibitors
DE3445532A1 (en) 1984-12-13 1986-06-19 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn HIRUDIN-PA, DESULFATOHIRUDINE-PA, METHOD FOR PRODUCTION AND PHARMACEUTICAL AGENTS THAT CONTAIN THESE ACTIVE SUBSTANCES
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3738541A1 (en) 1987-11-13 1989-05-24 Hoechst Ag METHOD FOR INSULATING AND CLEANING HIRUDINE
FR2593518B1 (en) 1985-05-02 1989-09-08 Transgene Sa VECTORS FOR THE EXPRESSION AND SECRETION OF HIRUDIN BY TRANSFORMED YEASTS
MY101203A (en) 1985-12-12 1991-08-17 Ucp Gen Pharma Ag Production of thrombin iinhibitors.
MC1834A1 (en) 1986-07-10 1988-06-03 Transgene Sa DNA FUNCTIONAL BLOCK AND PLASMID ENCODING HIRUDINE, TRANSFORMED YEAST, PROCESS FOR PREPARING HIRUDINE, HIRUDINE OBTAINED AND ITS USE
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
AU604925B2 (en) 1988-02-23 1991-01-03 Schering Aktiengesellschaft A hirudin derivative
AU614121B2 (en) 1988-05-04 1991-08-22 Novartis Ag Improvements in the production of polypeptides
GB8817161D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Modified proteins
GB8817160D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Novel proteins
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
HUT55799A (en) * 1988-09-29 1991-06-28 Biogen Inc Process for producing hirudine-like peptides
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
FR2645175B1 (en) 1989-03-31 1994-02-18 Transgene Sa STRAIN OF SACCHAROMYCES CEREVISIA PRODUCING A HETEROLOGOUS PROTEIN AND PROCESS FOR PREPARING SAID HETEROLOGOUS PROTEIN BY FERMENTATION OF SAID STRAIN
US5096092A (en) * 1990-03-13 1992-03-17 Mmm, Ltd. Food dispensing apparatus utilizing inflatable bladder
TW201303B (en) 1990-07-05 1993-03-01 Hoffmann La Roche
EP0511393B1 (en) 1990-11-08 1996-07-31 Japan Energy Corporation Hirudine mutant, production thereof, anticoagulant, secretory vector, microorganism transformed by said vector, and production of product from said microorganism
DE4041185A1 (en) * 1990-12-21 1992-06-25 Knoll Ag USE OF HIRUDINE AND ITS MUTEINS FOR COMBINATION TREATMENT OF TUMORS
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (en) 1991-08-28 1991-08-28 Astra Ab NEW ISOSTERIC PEPTIDES
ZA928581B (en) 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (en) 1991-12-04 1991-12-04 Astra Ab NEW PEPTIDE DERIVATIVES
JPH08501057A (en) 1992-03-04 1996-02-06 ヂョヂセルクタトー インテーゼット カーエフテー Novel anticoagulant factor peptide derivative, pharmaceutical composition containing the same, and method for producing the same
TW223629B (en) 1992-03-06 1994-05-11 Hoffmann La Roche
EP0592358B1 (en) 1992-09-04 2000-10-11 Novartis AG Process for the production of protease inhibitors
AU675981B2 (en) 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9303275D0 (en) 1993-02-18 1993-04-07 Ciba Geigy Ag Pharmaceutical compositions
SE9301916D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDES DERIVATIVES
DE4321444A1 (en) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmaceutical preparation
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
GB9401448D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Stable dry powders
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (en) 1994-06-17 1995-12-21 Basf Ag New thrombin inhibitors, their production and use
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
CA2211109A1 (en) 1995-02-17 1996-08-22 Basf Aktiengesellschaft Novel thrombin inhibitors
SE9600216D0 (en) 1996-01-18 1996-01-18 Hans Arne Hansson Control of healing processes
EP0915698A4 (en) 1996-05-01 1999-08-11 Lilly Co Eli Therapeutic treatment for vegf related diseases
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
DE10033195A1 (en) 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunctional fusion proteins from hirudin and TAP
WO2002028387A1 (en) 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0503829A2 (en) * 1991-03-08 1992-09-16 Ciba-Geigy Ag Hirudin for the inhibition of cancer metastasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLEGRINI ET AL., CANCER CHEMOTHER PHARMACOL, vol. 53, 2004, pages 261 - 266, XP003002323 *
ESUMI ET AL., CANCER RES., vol. 51, no. 17, 1991, pages 4549 - 4556, XP000128082 *
LOKICH ET AL., ANN. ONCOL., vol. 8, no. 1, 1997, pages 15 - 25, XP003002324 *

Also Published As

Publication number Publication date
IL178578A (en) 2013-06-27
ZA200609219B (en) 2012-02-29
WO2005099749A2 (en) 2005-10-27
EP1753291A4 (en) 2009-08-12
JP2007532646A (en) 2007-11-15
US7795205B2 (en) 2010-09-14
NZ551146A (en) 2009-04-30
TW200538466A (en) 2005-12-01
TWI362941B (en) 2012-05-01
US20110224150A1 (en) 2011-09-15
AU2005232625B2 (en) 2011-07-28
CA2562756C (en) 2011-08-23
US20090269422A1 (en) 2009-10-29
MY146091A (en) 2012-06-29
AU2005232625A1 (en) 2005-10-27
EP1753291A2 (en) 2007-02-21
CA2562756A1 (en) 2005-10-27
US20050233966A1 (en) 2005-10-20
SG160323A1 (en) 2010-04-29
BRPI0509876A (en) 2007-10-16
IL178578A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
WO2006091395A3 (en) Inhibitors of akt activity
WO2008070016A3 (en) Inhibitors of akt activity
WO2006135627A3 (en) Inhibitors of akt activity
MX2009012155A (en) A synergistic pharmaceutical combination for the treatment of cancer.
WO2006110638A3 (en) Inhibitors of akt activity
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
WO2007117996A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2005099749A3 (en) Methods for controlling angiogenesis and cell proliferation
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008125800A3 (en) Mmp activated vascular disrupting agents
MX2008011454A (en) Novel use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses.
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007508384

Country of ref document: JP

Ref document number: 2562756

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 178578

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200609219

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 551146

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005763698

Country of ref document: EP

Ref document number: 12006502242

Country of ref document: PH

Ref document number: 2005232625

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005232625

Country of ref document: AU

Date of ref document: 20050405

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005232625

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005763698

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0509876

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载